ArticleClinical & experimental metastasis2020
Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study.
Article in Clinical & experimental metastasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases.JNCI cancer spectrum · 2023Trial
- Outcome of CyberKnife stereotactic radiosurgery for the brain metastases in patients with Li Fraumeni syndrome.Journal of neuro-oncology · 2026Article
- Radionecrosis risk and local control after CyberKnifeRadiation oncology (London, England) · 2026Article
- Optimizing anisotropic margins in single-isocenter multiple brain metastases radiosurgery using regressor strategies: A multi-institutional validation study.Journal of applied clinical medical physics · 2025Article
- Investigation of the risk factors in the development of radionecrosis in patients with brain metastases undergoing stereotactic radiotherapy.The British journal of radiology · 2024Article
- Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.Cancers · 2023Article
- Stereotactic Radiation Therapy of Single Brain Metastases: A Literature Review of Dosimetric Studies.Cancers · 2023Review
- Stereotactic Radiosurgery as Treatment for Brain Metastases: An Update.Asian journal of neurosurgery · 2023Review
- Article
- Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases.Radiation oncology (London, England) · 2022Article
- Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review.Cancers · 2021Review
- Single-fraction versus hypofractionated gamma knife radiosurgery for small metastatic brain tumors.Clinical & experimental metastasis · 2021Article
- Clinical and volumetric predictors of local control after robotic stereotactic radiosurgery for cerebral metastases: active systemic disease may affect local control in the brain.Radiology and oncology · 2020Article
- A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases.Neuro-oncology advancesArticle
- Comparison of 2 stereotactic radiotherapy regimens for brain metastases: Is higher always better?Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare the local control and brain radionecrosis in patients with brain metastasis primarily treated by single-fraction radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (HFSRT). Between January 2012 and December 2017, 179 patients with only 1-3 brain metastases (total: 287) primarily treated by SRS (14 Gy) or HFSRT (23.1 Gy in 3 fractions of 7.7 Gy, every other day) were retrospectively analyzed in a single center. Follow-up imaging data were available in 152 patients with 246 lesions. The corresponding Biological Effective Dose (BED) were 33.6 Gy and 40.9 Gy respectively for SRS and HFSRT group, assuming an α/β of 10 Gy. Local control (LC) and risk of radionecrosis (RN) were calculated by the Kaplan-Meier method. The actuarial local control rates at 6 and 12 months were 94% and 88.1% in SRS group, and 87.6% and 78.4%, in HFSRT group (p = 0.06), respectively. Only the total volume of edema was associated with worse LC (p = 0.01, HR 1.02, 95% CI [1.004-1.03]) in multivariate analysis. Brain radionecrosis occurred in 1 lesion in SRS group and 9 in HFSRT group. Median time to necrosis was 5.5 months (range 1-9). Only the volume of GTV was associated with RN (p = 0.02, HR 1.09, 95% CI [1.01-1.18]) in multivariate analysis. Multi-fraction SRT dose of 23.31 Gy in 3 fractions has similar efficacy to single-fraction SRT dose of 14 Gy in patients with brain metastases. A slightly higher occurrence of radionecrosis appeared in HFSRT group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.